A Randomised Trial Investigating the Additional Benefit of Hydroxychloroquine(HCQ)to Short Course Radiotherapy (SCRT) in Patients Aged 70 Years and Older With High Grade Gliomas (HGG)

Exclusion Criteria

• •Concurrent psoriasis unless the disease is well controlled and patient is under the care of a specialist for the disorder who agrees to monitor for exacerbations
• •Prior macular degeneration or diabetic retinopathy
• •Concurrent serious infection or medical illness that would preclude study therapy
• •Another malignancy within the past 5 years except for curatively treated carcinoma in situ or basal cell carcinoma of the skin
• •Porphyria
• •Glucose- 6 phosphate dehydrogenase (G6PD) deficiency
• •Alcoholic liver disease
• •Any other concurrent severe/uncontrolled medical conditions
• •Currently taking amiodarone
• •Prior radiotherapy, chemotherapy, immunotherapy, biologic agents (e.g., immunotoxins, immunoconjugates, antisense agents, peptide receptor antagonists, interferons, interleukins, tumour-infiltrating lymphocytes, lymphokine-activated killer cell therapy, or gene therapy), or hormonal therapy for brain tumour
• •Prior polifeprosan 20 with carmustine implant (Gliadel wafer) or GliaSite® brachytherapy
• •Concurrent cytochrome P450 enzyme-inducing anticonvulsant drugs (e.g., phenytoin, carbamazepine, phenobarbital, primidone, or oxcarbazepine)
• •Other concurrent chemotherapeutic or investigational agents for this cancer (Concurrent glucocorticoids will be allowed
• •Documented side effects to chloroquine or related agents.
• •Unable to give informed consent
• •Patients with a history of a psychological illness or condition that in the opinion of the investigator may adversely affect compliance with study medication